Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06052566 · ClinicalTrials.gov registry record · Phase 1
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT06052566 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 22 participants.
The verdict
NCT06052566, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
Interventions
- DRUG Efinopegdutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06052566
The ClinicalTrials.gov registry entry for NCT06052566 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Efinopegdutide is the first listed.
NCT06052566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06052566 about?
NCT06052566 is a clinical study titled "A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)". The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
What is the current status of trial NCT06052566?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-11-21. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT06052566?
The interventions under investigation include: Efinopegdutide (DRUG).
Who is sponsoring clinical trial NCT06052566?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.